Jim Simons Geron Corp Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$3.1 - $5.09 $2.42 Million - $3.98 Million	781,723 New	781,723 $3.31 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $48,922 - $58,322	24,100 Added 10.31%	257,800 $624,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $37,575 - $66,150	22,500 Added 10.65%	233,700 $547,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.65 $513,009 - $711,315	-431,100 Reduced 67.12%	211,200 $327,000
Q1 2022 May 13, 2022	BUY	$0.99 - $1.6 $391,644 - $632,960	395,600 Added 160.36%	642,300 $874,000
Q4 2021 Feb 11, 2022	BUY	$1.22 - $1.72 $300,974 - $424,324	246,700 New	246,700 $301,000
Q1 2021 May 13, 2021	SELL	$1.52 - $2.1 $1.49 Million - $2.06 Million	-982,500 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$1.55 - $2.05 $1.49 Million - $1.97 Million	961,624 Added 4606.36%	982,500 $1.56 Million
Q3 2020 Nov 13, 2020	SELL	$1.59 - $2.19 $11,607 - $15,987	-7,300 Reduced 25.91%	20,876 $36,000
Q2 2020 Aug 13, 2020	BUY	$1.05 - $2.18 $29,584 - $61,423	28,176 New	28,176 $61,000
Q1 2020 May 14, 2020	SELL	$0.89 - $1.49 $51,014 - $85,406	-57,320 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.27 - $1.54 $72,796 - $88,272	57,320 New	57,320 $78,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.53B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.